KRT5 and neoplasm: Limitations of this novel patient-derived model system are the restricted number of microtumors available for downstream analyses, the reduced expression of immune cell markers and NFkB signaling proteins, as well as the enhanced expression of CK5 and CK6 as compared to corresponding primary tumor tissue.